[Small-cell lung cancer: management and novelties]

Area of Science:

• Oncology
• Pulmonology
• Genetics

Background:

• Small cell lung cancer (SCLC) is an aggressive malignancy with historically poor prognoses, often diagnosed at advanced stages.
• Despite low-dose CT screening, most patients present with metastatic disease, highlighting unmet needs in early detection and treatment.
• Advances in high-throughput sequencing are improving our understanding of SCLC biology.

Purpose of the Study:

• To provide a comprehensive review of small cell lung cancer.
• To discuss current and emerging therapeutic strategies.
• To highlight innovative treatments and future directions in SCLC management.

Main Methods:

• Literature review of epidemiological data.
• Analysis of molecular pathology findings.
• Review of clinical management guidelines and ongoing clinical trials for SCLC.

Main Results:

• SCLC has a low 5-year survival rate (<20%), with most cases diagnosed at metastatic stages.
• Immune checkpoint inhibitors have significantly improved outcomes for extensive-stage SCLC.
• Radiation therapy remains a crucial component of multimodal treatment across all stages.

Conclusions:

• SCLC management is evolving, with significant progress in immunotherapy for advanced disease.
• Targeted genetic therapies show promise as future treatment alternatives.
• A multidisciplinary approach integrating surgery, radiation, chemotherapy, and immunotherapy is essential for optimal SCLC patient care.